🔎 Trials Near Me

ホーム › 急性骨髄性白血病 › ミシガン州

ミシガン州における急性骨髄性白血病の臨床試験

ミシガン州内の拠点で、急性骨髄性白血病に関する24件の研究が参加者を募集しています。

ミシガン州内の都市

公式研究テキスト(英語)

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • 他3件
被験者募集中第2相
60歳以上 · 全性別 · 2026/10/02更新 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • MyMichigan Medical Center Gratiot, Alma
  • MyMichigan Medical Center Alpena, Alpena
  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • 他68件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • 他6件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Henry Ford Health System, Detroit
  • Trinity Health Michigan Heart - Ann Arbor Campus, Ypsilanti
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • 他14件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • 他6件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea
  • 他11件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
  • Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
  • Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton
  • 他9件
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • C S Mott Children's Hospital, Ann Arbor
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • Bronson Methodist Hospital, Kalamazoo
  • 他1件
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT06969430

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • C S Mott Children's Hospital, Ann Arbor
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • Bronson Methodist Hospital, Kalamazoo
被験者募集中第3相
1歳〜25歳 · 全性別 · 2026/09/04更新 · NCT07022678

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • C S Mott Children's Hospital, Ann Arbor
  • Children's Hospital of Michigan, Detroit
  • Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
  • 他2件
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • C.S. Mott Children's Hospital, Ann Arbor
  • Children's Hospital of Michigan, Detroit
被験者募集中第3相
29 Days – 21 Years · 全性別 · 2026/08/24更新 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Michigan, Ann Arbor
  • Wayne State University School of Medicine, Detroit
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Karmanos Cancer Institute, Detroit
  • Henry Ford Cancer Institute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

  • START Midwest, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/07更新 · NCT07751991

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • Henry Ford Cancer Institute, Detroit
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/17更新 · NCT05429632

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Michigan, Ann Arbor
  • Children's Hospital of Michigan, Detroit
  • Henry Ford Health System, Detroit
  • 他2件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

  • University of Michigan, Ann Arbor
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/15更新 · NCT05768932

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

  • West Michigan Cancer Center, Kalamazoo
被験者募集中観察研究
18歳以上 · 全性別 · 2026/05/07更新 · NCT02269592

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Michigan Comprehensive Cancer Center, Ann Arbor
  • Karmanos Cancer Institute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184

HPC Offered for PRESERVE Expansion

  • Henry Ford Health, Detroit
被験者募集中観察研究
12歳〜80歳 · 全性別 · 2025/08/28更新 · NCT07145411

ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。